<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82675">
  <stage>Registered</stage>
  <submitdate>18/03/2008</submitdate>
  <approvaldate>3/04/2008</approvaldate>
  <actrnumber>ACTRN12608000160336</actrnumber>
  <trial_identification>
    <studytitle>A prospective study of the impact upon serum electrolyte and magnesium levels of using magnesium sulfate for bowel preparation for colonoscopy.</studytitle>
    <scientifictitle>A prospective study of the impact upon serum electrolyte and magnesium levels of using magnesium sulfate for bowel preparation for colonoscopy.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Colonoscopy</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Normal oral and gastrointestinal development and function</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Colocap Balance (TM) 61.75gm magnesium sulfate, encapsulated (65 capsules). Patients will take 65 capsules orally, in batches of 5 with 250ml fluid, every 15 minutes, over a period of approximately 3 hours.</interventions>
    <comparator>Not applicable.</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To assess the difference in serum magnesium, urea, creatinine and electrolytes before and after ingesting 61.75gm dried magnesium sulfate.</outcome>
      <timepoint>PRE: Up to one week prior to taking bowel preparation, and POST: during colonoscopy procedure.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To assess the efficacy of the preparation using the colonoscopists evaluation of the quality of the bowel clean.</outcome>
      <timepoint>During colonoscopy procedure.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To assess the acceptability of the bowel preparation to patients using their reports of palatability, ease of use and tolerability.</outcome>
      <timepoint>After taking bowel preparation, immediately before procedure.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Presenting for elective colonoscopy.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Renal insufficiency; current chronic inflammatory bowel disease.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Diagnosis</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>28/02/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Colocap Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress>Unit 7, 176 Main Street
Osborne Park  WA  6017</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Colocap Pharmaceuticals</fundingname>
      <fundingaddress>Unit 7, 176 Main Street
Osborne Park  WA  6017</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>St John of God Health Care Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec>EC00286</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Leon Levitt</name>
      <address>Colocap Pharmaceuticals
Unit 7, 176 Main Street
Osborne Park  WA  6017</address>
      <phone>(08) 9349 2700</phone>
      <fax />
      <email>leon@colocap.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Shannon Meyerkort</name>
      <address>Colocap Pharmaceuticals
Unit 7, 176 Main Street
Osborne Park WA 6017</address>
      <phone>(08) 9349 2700</phone>
      <fax />
      <email>shannon@colocap.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Shannon Meyerkort</name>
      <address>Colocap Pharmaceuticals
Unit 7, 176 Main Street
Osborne Park WA 6017</address>
      <phone>(08) 9349 2700</phone>
      <fax>(08) 9349 2711</fax>
      <email>shannon@colocap.com.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>